<!DOCTYPE html>
<html lang="zh-TW">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>台灣與國際罕見疾病／孤兒藥制度比較</title>
    <meta name="description" content="台灣、歐美、日、加、澳罕見疾病與孤兒藥制度最新比較：定義、激勵、法源、給付與政策架構。">
    <meta data-version="1.2" data-last-updated="2025-09-09">
    <style>
        :root {
            --c-primary:#2563eb;
            --c-secondary:#0d6efd;
            --c-bg:#f5f7fa;
            --c-border:#e2e8f0;
            --c-danger:#dc3545;
            --c-warn:#f59e0b;
            --c-ok:#059669;
            --c-info:#0ea5e9;
            --c-muted:#64748b;
            --c-highlight:#fff8e1;
            --radius:10px;
        }
        body {
            font-family:"Microsoft JhengHei",Arial,sans-serif;
            margin:0;
            padding:20px;
            background:var(--c-bg);
            line-height:1.65;
            color:#1e293b;
        }
        .container {
            max-width:1450px;
            margin:0 auto;
            background:#fff;
            padding:32px 40px 60px;
            border-radius:var(--radius);
            box-shadow:0 6px 28px -8px rgba(0,0,0,.12);
            position:relative;
        }
        h1 {
            margin:0 0 28px;
            text-align:center;
            font-size:2.25rem;
            background:linear-gradient(135deg,var(--c-primary),#0ea5e9);
            -webkit-background-clip:text;
            color:transparent;
            letter-spacing:.5px;
        }
        .meta-bar {
            display:flex;
            flex-wrap:wrap;
            gap:16px;
            font-size:.85rem;
            background:#eff6ff;
            border:1px solid #bfdbfe;
            padding:10px 16px;
            border-radius:var(--radius);
            margin-bottom:25px;
        }
        .badge {
            display:inline-block;
            padding:3px 10px 4px;
            font-size:.7rem;
            letter-spacing:.5px;
            border-radius:999px;
            background:#1d4ed8;
            color:#fff;
            margin-right:6px;
            vertical-align:middle;
        }
        .toc {
            background:#f1f5f9;
            border:1px solid var(--c-border);
            padding:22px 26px;
            border-radius:var(--radius);
            margin-bottom:38px;
            position:relative;
        }
        .toc h2 {
            margin:0 0 14px;
            font-size:1.25rem;
            color:#0f172a;
            display:flex;
            align-items:center;
            gap:8px;
        }
        .toc ul {
            list-style:none;
            padding:0;
            margin:0;
            columns:2;
        }
        .toc li {
            margin:6px 0;
            break-inside:avoid;
        }
        .toc a {
            text-decoration:none;
            color:var(--c-secondary);
            font-weight:500;
            position:relative;
            padding-left:4px;
        }
        .toc a:hover {
            text-decoration:underline;
            color:#1d4ed8;
        }
        .law-section {
            border:1px solid var(--c-border);
            border-radius:var(--radius);
            margin-bottom:55px;
            overflow:hidden;
            background:#ffffff;
        }
        .law-header {
            margin:0;
            padding:18px 24px;
            background:linear-gradient(120deg,#1e3a8a,#1d4ed8 50%,#2563eb);
            color:#fff;
            font-size:1.45rem;
            letter-spacing:.5px;
            display:flex;
            justify-content:space-between;
            flex-wrap:wrap;
            gap:12px;
        }
        .law-meta {
            background:#f8fafc;
            padding:14px 22px;
            font-size:.85rem;
            border-top:1px solid var(--c-border);
            border-bottom:1px solid var(--c-border);
            color:#475569;
            line-height:1.5;
        }
        .law-content {
            padding:30px 34px 40px;
        }
        .article {
            margin-bottom:32px;
            background:#ffffff;
            border:1px solid #e2e8f0;
            border-left:5px solid var(--c-primary);
            border-radius:6px;
            padding:18px 22px 20px;
            position:relative;
        }
        .article-title {
            font-weight:600;
            font-size:1.05rem;
            margin:0 0 14px;
            color:#0f172a;
            display:flex;
            align-items:center;
            gap:8px;
            flex-wrap:wrap;
        }
        .article-title .small-label {
            background:#e0f2fe;
            color:#0369a1;
            font-size:.6rem;
            padding:2px 6px 3px;
            border-radius:4px;
            letter-spacing:.5px;
        }
        .bilingual-content {
            display:grid;
            grid-template-columns:1fr 1fr;
            gap:20px;
        }
        .original-text, .translation {
            padding:14px 16px 16px;
            border-radius:8px;
            font-size:.9rem;
            position:relative;
            line-height:1.55;
        }
        .original-text {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
        }
        .translation {
            background:#fffceb;
            border:1px solid #fde68a;
        }
        .lang-label {
            font-size:.62rem;
            font-weight:600;
            letter-spacing:.8px;
            color:#334155;
            background:#e2e8f0;
            padding:4px 8px;
            border-radius:999px;
            display:inline-block;
            margin-bottom:10px;
        }
        .highlight-box {
            background:#eef6ff;
            padding:18px 22px;
            border-left:6px solid #2563eb;
            border-radius:8px;
            margin:30px 0 10px;
            font-size:.92rem;
        }
        .highlight-box h3 {
            margin:0 0 14px;
            font-size:1rem;
            color:#1e3a8a;
            letter-spacing:.5px;
        }
        .point-list {
            margin:0;
            padding:0;
            list-style:none;
            display:grid;
            gap:10px;
        }
        .point-item {
            position:relative;
            padding-left:18px;
            font-size:.9rem;
        }
        .point-item:before {
            content:"◆";
            font-size:.55rem;
            color:#2563eb;
            position:absolute;
            left:0;
            top:5px;
        }
        .comparison-wrapper {
            overflow-x:auto;
            margin-top:10px;
        }
        table.comparison-table {
            width:100%;
            border-collapse:collapse;
            font-size:.82rem;
            min-width:1150px;
        }
        .comparison-table th, .comparison-table td {
            border:1px solid #e2e8f0;
            padding:9px 9px;
            text-align:left;
            vertical-align:top;
        }
        .comparison-table th {
            background:#1e3a8a;
            color:#ffffff;
            position:sticky;
            top:0;
            z-index:2;
            font-weight:600;
            letter-spacing:.5px;
        }
        .comparison-table tbody tr:nth-child(even) {
            background:#f8fafc;
        }
        .comparison-table td .note-inline {
            display:block;
            font-size:.65rem;
            color:#64748b;
            margin-top:4px;
            line-height:1.25;
        }
        .footnotes {
            background:#f8fafc;
            border:1px solid var(--c-border);
            padding:24px 28px 30px;
            border-radius:var(--radius);
            font-size:.75rem;
            line-height:1.45;
            margin-top:60px;
        }
        .footnotes h3 {
            margin:0 0 14px;
            font-size:.92rem;
            color:#0f172a;
        }
        .footnotes ol { margin:0; padding-left:18px; }
        .footnotes li { margin:6px 0; }
        .callout {
            border:1px solid #cbd5e1;
            background:#ffffff;
            padding:16px 18px;
            border-radius:8px;
            margin:24px 0;
            display:flex;
            gap:14px;
            font-size:.85rem;
            position:relative;
        }
        .callout.info { border-color:#93c5fd; background:#eff6ff; }
        .callout.warn { border-color:#fcd34d; background:#fffbeb; }
        .callout.danger { border-color:#fca5a5; background:#fef2f2; }
        .callout strong { color:#0f172a; }
        .legend {
            display:flex;
            flex-wrap:wrap;
            gap:10px;
            margin:14px 0 4px;
            font-size:.62rem;
        }
        .legend span {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
            padding:4px 8px;
            border-radius:6px;
            display:flex;
            align-items:center;
            gap:4px;
        }
        .legend code {
            background:#e2e8f0;
            padding:2px 4px;
            border-radius:4px;
            font-size:.6rem;
        }
        .revision-log {
            margin-top:55px;
            background:#ffffff;
            border:1px solid #e2e8f0;
            padding:20px 24px 26px;
            border-radius:var(--radius);
            font-size:.8rem;
        }
        .revision-log h3 {
            margin:0 0 12px;
            font-size:.95rem;
        }
        .revision-log ul {
            margin:0;
            padding-left:18px;
            line-height:1.5;
        }
        .source-links {
            display:grid;
            gap:14px;
            grid-template-columns:repeat(auto-fill,minmax(260px,1fr));
            margin-top:14px;
        }
        .source-card {
            background:#f1f5f9;
            border:1px solid #e2e8f0;
            border-radius:8px;
            padding:12px 14px 14px;
            font-size:.68rem;
            line-height:1.35;
            position:relative;
        }
        .source-card h4 {
            margin:0 0 6px;
            font-size:.72rem;
            color:#0f172a;
        }
        .source-card a {
            word-break:break-all;
            color:#1d4ed8;
            text-decoration:none;
        }
        .source-card a:hover { text-decoration:underline; }
        .disclaimer {
            margin-top:60px;
            padding:20px 24px;
            background:#fef2f2;
            border:1px solid #fecaca;
            border-radius:var(--radius);
            font-size:.74rem;
            line-height:1.5;
            color:#991b1b;
        }
        .back-to-top {
            position:fixed;
            right:26px;
            bottom:26px;
            width:50px;
            height:50px;
            background:#2563eb;
            color:#fff;
            border:none;
            border-radius:50%;
            cursor:pointer;
            font-size:18px;
            display:none;
            box-shadow:0 4px 16px -4px rgba(0,0,0,.35);
            transition:.25s;
        }
        .back-to-top:hover { background:#1d4ed8; transform:translateY(-3px); }
        mark {
            background:#fde68a;
            padding:1px 3px;
            border-radius:4px;
        }
        .label {
            display:inline-block;
            font-size:.55rem;
            padding:3px 6px;
            background:#e2e8f0;
            color:#334155;
            border-radius:4px;
            letter-spacing:.5px;
            margin-left:6px;
        }
        @media (max-width:980px){
            .bilingual-content { grid-template-columns:1fr; }
            .toc ul { columns:1; }
            .law-content { padding:26px 22px 30px; }
            .article { padding:16px 16px 18px; }
            h1 { font-size:1.9rem; }
        }
        @media (max-width:600px){
            body { padding:12px; }
            .container { padding:22px 20px 50px; }
            .law-header { font-size:1.15rem; }
        }
    </style>
</head>
<body>
  <div class="container">
    <h1>🌐 台灣優先視角：國際罕見疾病／孤兒藥制度比較（修訂增補版）</h1>

    <div class="meta-bar">
      <div><span class="badge">VERSION</span> 1.2（增補台灣優先）</div>
      <div><span class="badge" style="background:#059669;">更新日期</span> 2025-09-09</div>
      <div><span class="badge" style="background:#0ea5e9;">涵蓋</span> 台灣 / 美國 / 歐盟 / 日本 / 加拿大 / 澳洲</div>
      <div><span class="badge" style="background:#9333ea;">語言</span> 中文為主 + 關鍵英文摘要</div>
    </div>

    <div class="callout info">
      <div><strong>說明：</strong>本版依您要求「台灣置頂」，全面整合最新可公開資訊，並對「定義差異、激勵工具屬性、給付特徵」進行結構化呈現；已排除先前過時敘述，並標註政策性 vs 法定性差異。若將用於正式政策報告，建議再行內部法務複核。</div>
    </div>

    <div class="legend">
      <span><code>法定</code> = 法條明訂</span>
      <span><code>政策</code> = 行政/實務運作</span>
      <span><code>觀察</code> = 分析性補述</span>
    </div>

    <div class="toc">
      <h2>📋 目錄</h2>
      <ul>
        <li><a href="#taiwan-rare-disease-act">一、台灣罕見疾病防治及藥物制度</a></li>
        <li><a href="#usa-orphan-drug-act">二、美國孤兒藥法 (Orphan Drug Act)</a></li>
        <li><a href="#eu-orphan-regulation">三、歐盟孤兒藥規則 (Reg. 141/2000)</a></li>
        <li><a href="#japan-intractable-disease-act">四、日本《難病法》與指定難病</a></li>
        <li><a href="#canada-rare-strategy">五、加拿大罕見疾病策略</a></li>
        <li><a href="#australia-orphan-program">六、澳洲 TGA 孤兒藥制度</a></li>
        <li><a href="#comparison-table">七、比較總表</a></li>
        <li><a href="#sources">八、來源與參考</a></li>
        <li><a href="#revision-log">九、修訂紀錄</a></li>
        <li><a href="#disclaimer">十、免責聲明</a></li>
      </ul>
    </div>

    <!-- TAIWAN -->
    <section id="taiwan-rare-disease-act" class="law-section">
      <h2 class="law-header">一、台灣 罕見疾病防治及藥物制度（Rare Disease Prevention and Orphan Drugs Act）</h2>
      <div class="law-meta">
        初訂：2000 年 | 主管機關：衛生福利部（MOHW） | 相關法源：罕見疾病防治及藥物法、全民健康保險法、產業創新條例、藥事法、菸品健康福利捐條例
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">（1）定義與指定機制 <span class="small-label">法定 + 行政準則</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">中文（實務摘要）</div>
              罕見疾病之認定依法第 3 條授權中央主管機關訂定標準；現行行政基準採「國內盛行率 ≤ 1/10,000」並考量：疾病嚴重性、診斷困難度、治療可近性、是否缺乏替代療法。<br><br>
              指定程序：疾病資料彙整 → 申請/審議（專家審查會）→ 公告列入罕見疾病清單 → 相對應藥物得申請為「罕見疾病用藥」。
            </div>
            <div class="translation">
              <div class="lang-label">EN Summary</div>
              Taiwan defines a rare disease administratively as a condition with domestic prevalence ≤1/10,000 plus qualitative criteria (severity, diagnostic difficulty, lack of effective therapy). Designation involves expert review and official listing; orphan drugs for listed diseases may access specific funding and reimbursement pathways.
            </div>
          </div>
        </div>

        <div class="article">
          <div class="article-title">（2）法定支持與財源架構 <span class="small-label">法定 / 政策</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">中文</div>
              1. 專款基金：設置「罕見疾病防治基金」支應研究、教育、患者支持（法定來源：政府預算、捐贈、利息等）。<br>
              2. 醫療給付：健保對多數罕見疾病藥品採請領審查制，核准後由健保支應，高額新藥常以「專案支付」或「風險分攤」模式。<br>
              3. 財務來源補強：菸品健康福利捐挹注公共衛生支出（間接支持罕病資源配置）。<br>
              4. 自付減免：對符合條件罕病患者之醫療費用部分或全部減免。<br>
              5. 產業誘因：可併用「產業創新條例」研發投抵與藥事法下快速審查機制。
            </div>
            <div class="translation">
              <div class="lang-label">EN Summary</div>
              Funding pillars: (a) dedicated rare disease fund (government + donations), (b) National Health Insurance (NHI) reimbursement with prior review, (c) public health surcharges (tobacco) supporting broader allocation, (d) out-of-pocket relief, (e) R&D tax incentives via general innovation statute, (f) managed entry / risk‑sharing for high-cost therapies.
            </div>
          </div>
        </div>

        <div class="article">
          <div class="article-title">（3）藥物審查與給付流程 <span class="small-label">流程摘要</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">中文</div>
              (A) 藥證：若國際已上市，提交境外臨床資料 + 品質文件；必要時得加速或簡化審查。<br>
              (B) 給付：提交藥物經濟評估（具挑戰性因病患少），採「臨床必要性 + 替代性不足 + 預算影響」綜合判斷。<br>
              (C) 常見模式：資料限制 → 採條件式給付（含療效再評估節點）。<br>
              (D) 風險分攤：成果導向 (Outcome-based) 或支出上限 (Cap) 形式逐步增加。<br>
              (E) 實證補強：鼓勵患者登錄（追蹤療效與安全）。
            </div>
            <div class="translation">
              <div class="lang-label">EN Summary</div>
              Regulatory + reimbursement path: accelerated review of foreign data; HTA applies modified standards due to limited evidence; conditional reimbursement with outcome re‑assessment; evolving risk‑sharing contracts; patient registries reinforce real‑world evidence.
            </div>
          </div>
        </div>

        <div class="article">
          <div class="article-title">（4）激勵機制分類 <span class="small-label">解析</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">中文</div>
              1. 研發支持：研究計畫補助（與科技部/衛福部合作）<br>
              2. 審查支持：專案窗口、必要時加速審查（政策性）<br>
              3. 財務：給付減免、基金補助、產創條例研發抵減（非專屬罕病）<br>
              4. 資料：患者登錄與自然史研究（提升後續評價精準度）<br>
              5. 社會支持：罕病基金會、患者協會心理/法規諮詢<br>
              6. 注意：與美/歐不同，無獨立「Orphan Market Exclusivity」，屬「給付保護 + 審查協助」模式。
            </div>
            <div class="translation">
              <div class="lang-label">EN Summary</div>
              Incentives emphasize access and coverage rather than statutory exclusivity: research grants, expedited scientific dialogue, financial relief, registry data infrastructure, patient advocacy integration. No separate orphan exclusivity akin to US/EU.
            </div>
          </div>
        </div>

        <div class="article">
          <div class="article-title">（5）治理與監測 <span class="small-label">政策</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">中文</div>
              - 專家審查委員會：審疾病與藥物納入性。<br>
              - 成本監測：高價基因與細胞療法導入後，採「病例數推估 + 年度預算影響」模型。<br>
              - 實證循環：收集真實世界資料（RWD）進行再評估，可能調整給付條件。<br>
              - 公共透明：公告罕病清單、用藥審查原則與補助規定。
            </div>
            <div class="translation">
              <div class="lang-label">EN Summary</div>
              Governance relies on expert panels, budget impact modeling for advanced therapies, iterative RWE-based re‑assessment, and public transparency of lists and criteria.
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>台灣制度特色與挑戰</h3>
          <ul class="point-list">
            <li class="point-item"><strong>特色：</strong>定義最嚴格（≤1/10,000），確保資源聚焦高未滿足需求族群。</li>
            <li class="point-item">整合型：醫療給付 + 基金補助 + 社會支持同時運作。</li>
            <li class="point-item">可近性高：罕病藥物核准後多能迅速納入支付（相較多國等待期）。</li>
            <li class="point-item">成本壓力：新型基因/細胞療法單例超高額，推升財務永續壓力。</li>
            <li class="point-item">評估挑戰：臨床試驗規模小→需依自然史/國際資料補強。</li>
            <li class="point-item">未來焦點：資料整合、動態支付模式（Performance-based）與區辨「極罕病」（超低盛行）策略。</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- USA -->
    <section id="usa-orphan-drug-act" class="law-section">
      <h2 class="law-header">二、美國孤兒藥法 Orphan Drug Act (ODA)</h2>
      <div class="law-meta">
        制定：1983 年 | 主管：FDA OOPD | 最新主要影響：2017 稅制改革調整稅收抵免比例
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">Section 526 - 指定條件 <span class="small-label">摘要</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              Sponsor may request designation if intended for a rare disease (<200,000 people in the US) or inability to recover development costs from US sales.
            </div>
            <div class="translation">
              <div class="lang-label">中文</div>
              符合：① 患者數 <20 萬人 或 ② 銷售不足以回收成本，即可申請孤兒指定。
            </div>
          </div>
        </div>

        <div class="article">
          <div class="article-title">Section 527 - 7 年市場獨占 <span class="small-label">法定</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              7-year exclusivity for the same drug & same indication; exceptions for clinical superiority or supply issues.
            </div>
            <div class="translation">
              <div class="lang-label">中文</div>
              獲孤兒適應症核准後 7 年內，FDA 不核准同藥同適應症（特定例外）。
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>美國重點</h3>
          <ul class="point-list">
            <li class="point-item">定義：<200,000 人或無法回收成本（雙軌）</li>
            <li class="point-item">市場獨占：7 年（可與 Pediatric 6 個月 + Hatch-Waxman 資料保護疊加）</li>
            <li class="point-item">稅收抵免：合格臨床試驗支出上限 25%（TCJA 後）</li>
            <li class="point-item">其它：User Fee 減免、FDA Protocol Assistance、Grant Program</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- EU -->
    <section id="eu-orphan-regulation" class="law-section">
      <h2 class="law-header">三、歐盟孤兒藥規則 Regulation (EC) No 141/2000</h2>
      <div class="law-meta">
        生效：2000 年 | 主管：EMA (COMP) | 兒科完成可延長獨占至 12 年
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">Article 3 - 指定條件 <span class="small-label">法定</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              Life‑threatening / chronically debilitating & prevalence ≤5/10,000 OR insufficient return; AND no satisfactory method or significant benefit over existing.
            </div>
            <div class="translation">
              <div class="lang-label">中文</div>
              盛行率 ≤5/10,000 或 無足夠回報；且 無滿意療法或具顯著效益。
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>歐盟重點</h3>
          <ul class="point-list">
            <li class="point-item">市場獨占：10 年（第 6 年起可因失去「顯著效益」或供應不足縮短；兒科延 2 年）</li>
            <li class="point-item">激勵：集中審評、費用減免、Protocol Assistance、SME 支持</li>
            <li class="point-item">顯著效益（Significant Benefit）為後續維持排他核心判準</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Japan -->
    <section id="japan-intractable-disease-act" class="law-section">
      <h2 class="law-header">四、日本《難病法》與指定難病制度</h2>
      <div class="law-meta">
        制定：2014 / 施行：2015 | 主管：厚生労働省 | 焦點：醫療費助成＋研究登錄
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">指定難病主要要素 <span class="small-label">政策 + 法定條件</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">日文要旨</div>
              発病機序不明、治療確立無、長期療養要、患者数低（政策參考約人口 0.1% 以下）、客観的診断基準有。
            </div>
            <div class="translation">
              <div class="lang-label">中文</div>
              五要素並行：病因未明、無根治療法、需長期療養、患者數低（約人口 0.1% 以下階層參考）、有客觀診斷標準。
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>日本特色</h3>
          <ul class="point-list">
            <li class="point-item">重點在「助成與研究網絡」非市場獨占</li>
            <li class="point-item">設有全國患者登錄促進自然史與實證</li>
            <li class="point-item">所得與重症分類影響醫療費補助層級</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Canada -->
    <section id="canada-rare-strategy" class="law-section">
      <h2 class="law-header">五、加拿大罕見疾病國家策略</h2>
      <div class="law-meta">
        現況：無專屬孤兒藥法 | 2023 啟動 National Strategy (CAD 10 億 / 3 年)
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">制度狀態 <span class="small-label">政策</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">原背景</div>
              先前曾擬草案但未定案；採國際比較與個案式評估。
            </div>
            <div class="translation">
              <div class="lang-label">中文</div>
              無統一定義與排他；採一般藥品 8 年資料保護（兒科 +6 個月）而非孤兒專屬；策略重點：加速可及、協調 HTA、資料互通與患者參與。
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>加拿大重點</h3>
          <ul class="point-list">
            <li class="point-item">缺專法 → 激勵相對弱</li>
            <li class="point-item">透過聯邦資金支持省級協調</li>
            <li class="point-item">資料與公平可及為政策優先</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Australia -->
    <section id="australia-orphan-program" class="law-section">
      <h2 class="law-header">六、澳洲 TGA 孤兒藥制度</h2>
      <div class="law-meta">
        創立：1998 | 2017 改版 | 主管：TGA | 核心：費用減免 + 指定
      </div>
      <div class="law-content">

        <div class="article">
          <div class="article-title">指定條件 <span class="small-label">政策準則</span></div>
          <div class="bilingual-content">
            <div class="original-text">
              <div class="lang-label">EN</div>
              Prevalence <5/10,000 in Australia OR not commercially viable without incentives; serious condition; no alternative with comparable benefit.
            </div>
            <div class="translation">
              <div class="lang-label">中文</div>
              盛行率 <5/10,000 或缺乏商業可行性；屬嚴重疾病；且無具同等效益替代療法。
            </div>
          </div>
        </div>

        <div class="highlight-box">
          <h3>澳洲重點</h3>
          <ul class="point-list">
            <li class="point-item">無獨立法定孤兒市場獨占</li>
            <li class="point-item">提供評審費用減免與科學諮詢</li>
            <li class="point-item">可與優先/限縮審查路徑搭配</li>
          </ul>
        </div>

      </div>
    </section>

    <!-- Comparison Table -->
    <section id="comparison-table" class="law-section">
      <h2 class="law-header">七、各司法轄區比較總表（2025 更新）</h2>
      <div class="law-content">

        <div class="comparison-wrapper">
          <table class="comparison-table">
            <thead>
              <tr>
                <th>項目</th>
                <th>台灣</th>
                <th>美國</th>
                <th>歐盟</th>
                <th>日本</th>
                <th>加拿大</th>
                <th>澳洲</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td><strong>法規 / 制度</strong></td>
                <td>罕見疾病防治及藥物法</td>
                <td>Orphan Drug Act</td>
                <td>Reg. 141/2000</td>
                <td>難病法 + 指定難病</td>
                <td>National Strategy（政策）</td>
                <td>Orphan Drug Program（政策）</td>
              </tr>
              <tr>
                <td><strong>定義/門檻</strong></td>
                <td>盛行率 ≤1/10,000 + 質性判準</td>
                <td><200,000 或成本不可回收</td>
                <td>≤5/10,000 + 顯著效益判斷</td>
                <td>多要素（含患者低於約 0.1% 人口）</td>
                <td>無統一定義（參考國際）</td>
                <td><5/10,000 或無商業可行性</td>
              </tr>
              <tr>
                <td><strong>市場獨占</strong></td>
                <td>無獨立孤兒排他（一般資料保護）</td>
                <td>7 年孤兒排他</td>
                <td>10 年（可縮 / 兒科 12 年）</td>
                <td>無孤兒排他制度</td>
                <td>無（一般 8 年 + 兒科 6 月）</td>
                <td>無（費用減免為主）</td>
              </tr>
              <tr>
                <td><strong>資料 / 兒科延長</strong></td>
                <td>依藥事法一般規則</td>
                <td>Pediatric +6 月</td>
                <td>兒科 +2 年</td>
                <td>無專屬</td>
                <td>8 + 0.5 年（兒科）</td>
                <td>一般規則</td>
              </tr>
              <tr>
                <td><strong>稅務 / 財政激勵</strong></td>
                <td>研發投抵（產創條例泛用）</td>
                <td>研發臨床抵免 25%</td>
                <td>會員國視情況</td>
                <td>研究補助</td>
                <td>有限（專案資助）</td>
                <td>無專屬稅務</td>
              </tr>
              <tr>
                <td><strong>費用減免</strong></td>
                <td>審查費用減免（部分）</td>
                <td>User Fee 減免</td>
                <td>EMA 費用減免</td>
                <td>有</td>
                <td>個案</td>
                <td>大幅減免</td>
              </tr>
              <tr>
                <td><strong>加速 / 支援</strong></td>
                <td>專案審查 / 風險分攤</td>
                <td>Fast Track / BTD / Priority</td>
                <td>PRIME / Accelerated Assessment</td>
                <td>個案協調</td>
                <td>個案優先</td>
                <td>Priority / Provisional</td>
              </tr>
              <tr>
                <td><strong>給付模式</strong></td>
                <td>NHI 審議 + 基金補助</td>
                <td>保險多元（缺統一）</td>
                <td>會員國自訂</td>
                <td>助成制度</td>
                <td>省級差異</td>
                <td>PBS HTA 決策</td>
              </tr>
              <tr>
                <td><strong>風險分攤 / 成果付費</strong></td>
                <td>漸增（成果/上限）</td>
                <td>可（私商保險差異）</td>
                <td>多採 MEA (Managed Entry)</td>
                <td>有限</td>
                <td>探索中</td>
                <td>存在（HTA 談判）</td>
              </tr>
              <tr>
                <td><strong>患者登錄</strong></td>
                <td>推動整合平台</td>
                <td>多散狀 / NIH 支持</td>
                <td>Orphanet / EU 網絡</td>
                <td>指定難病登錄</td>
                <td>分散研究導向</td>
                <td>學會 / 專題</td>
              </tr>
              <tr>
                <td><strong>政策焦點（近期）</strong></td>
                <td>高額基因治療財務永續</td>
                <td>加速細胞 / 基因療法</td>
                <td>評估改革與適應性審查</td>
                <td>擴充登錄與公平助成</td>
                <td>統一可及與 HTA 協調</td>
                <td>成本與審查效率平衡</td>
              </tr>
            </tbody>
          </table>
        </div>

        <div class="callout warn">
          <strong>解讀提示：</strong>「市場獨占」與「資料保護」法律基礎不同；台灣著重支付保障與醫療可及，而非授予排他銷售權。
        </div>

      </div>
    </section>

    <!-- Sources -->
    <section id="sources" class="law-section">
      <h2 class="law-header">八、來源與參考連結</h2>
      <div class="law-content">

        <div class="source-links">
          <div class="source-card">
            <h4>台灣 罕見疾病法</h4>
            <a href="https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0020037" target="_blank">法規原文</a>
          </div>
          <div class="source-card">
            <h4>衛福部罕見疾病專區</h4>
            <a href="https://www.mohw.gov.tw" target="_blank">MOHW</a>
          </div>
          <div class="source-card">
            <h4>食藥署藥品資訊</h4>
            <a href="https://www.fda.gov.tw" target="_blank">TFDA</a>
          </div>
          <div class="source-card">
            <h4>健保署給付資料</h4>
            <a href="https://www.nhi.gov.tw" target="_blank">NHI</a>
          </div>
          <div class="source-card">
            <h4>菸品健康福利捐條例</h4>
            <a href="https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=L0070026" target="_blank">法源</a>
          </div>
          <div class="source-card">
            <h4>Statute for Industrial Innovation</h4>
            <a href="https://law.moj.gov.tw/LawClass/LawAll.aspx?pcode=J0080032" target="_blank">產創條例</a>
          </div>
          <div class="source-card">
            <h4>USA Orphan Drug Act</h4>
            <a href="https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title21-section360bb" target="_blank">21 U.S.C. 360bb–dd</a>
          </div>
          <div class="source-card">
            <h4>FDA OOPD</h4>
            <a href="https://www.fda.gov/industry/developing-products-rare-diseases-conditions" target="_blank">FDA Guidance</a>
          </div>
          <div class="source-card">
            <h4>Tax Cuts and Jobs Act</h4>
            <a href="https://www.congress.gov/bill/115th-congress/house-bill/1" target="_blank">TCJA 2017</a>
          </div>
          <div class="source-card">
            <h4>EU Reg. 141/2000</h4>
            <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32000R0141" target="_blank">EUR-Lex</a>
          </div>
          <div class="source-card">
            <h4>EU Orphan Designation</h4>
            <a href="https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation" target="_blank">EMA</a>
          </div>
          <div class="source-card">
            <h4>Paediatric Reg. 1901/2006</h4>
            <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32006R1901" target="_blank">EUR-Lex</a>
          </div>
          <div class="source-card">
            <h4>日本 難病法</h4>
            <a href="https://elaws.e-gov.go.jp/document?lawid=426AC0000000050" target="_blank">e-Gov</a>
          </div>
          <div class="source-card">
            <h4>日本 指定難病</h4>
            <a href="https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000084783.html" target="_blank">厚労省</a>
          </div>
          <div class="source-card">
            <h4>加拿大 罕病策略</h4>
            <a href="https://www.canada.ca/en/health-canada/news/2023/03/supporting-canadians-with-rare-diseases.html" target="_blank">News Release 2023</a>
          </div>
          <div class="source-card">
            <h4>Canada Orphan Policy Background</h4>
            <a href="https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/initiatives/orphan-drugs.html" target="_blank">Health Canada</a>
          </div>
          <div class="source-card">
            <h4>Australia Orphan Guidance</h4>
            <a href="https://www.tga.gov.au/resources/resource/guidance/orphan-drug-designation" target="_blank">TGA</a>
          </div>
          <div class="source-card">
            <h4>Australia Fee Relief</h4>
            <a href="https://www.tga.gov.au/how-we-regulate/fees/orphan-drugs" target="_blank">TGA Fees</a>
          </div>
          <div class="source-card">
            <h4>Orphanet</h4>
            <a href="https://www.orpha.net" target="_blank">Orphanet</a>
          </div>
          <div class="source-card">
            <h4>NORD</h4>
            <a href="https://rarediseases.org/" target="_blank">NORD</a>
          </div>
          <div class="source-card">
            <h4>EURORDIS</h4>
            <a href="https://www.eurordis.org/" target="_blank">EURORDIS</a>
          </div>
        </div>

        <div class="footnotes">
          <h3>註釋（Footnotes）</h3>
          <ol>
            <li>台灣盛行率門檻：行政認定原則（≤1/10,000）以確保資源焦點；法條授權主管機關訂定。</li>
            <li>台灣未設類似美/歐孤兒市場獨占；給付保障與資料保護為不同法律層次。</li>
            <li>美國稅收抵免：2017 前 50%，TCJA 後調整為 25% 上限。</li>
            <li>日本「患者數」為政策參考階層（約 0.1% 人口），非唯一硬性數值。</li>
            <li>加拿大無法定統一定義；策略以協調資源與加速可及。</li>
            <li>澳洲 2017 改版後採盛行率 <5/10,000；取消舊有個別人數表述。</li>
            <li>歐盟顯著效益（Significant Benefit）影響維持獨占之資格。</li>
            <li>「風險分攤」術語涵蓋成果型與支出上限型，多國尚在演化。</li>
          </ol>
        </div>

      </div>
    </section>

    <!-- Revision Log -->
    <section id="revision-log" class="revision-log">
      <h3>九、修訂紀錄</h3>
      <ul>
        <li><strong>v1.2 (2025-09-09)：</strong>新增台灣置頂專節（定義、基金、給付、激勵、治理）；調整比較表欄位；補充財源法源；細化風險分攤與 RWD 描述。</li>
        <li><strong>v1.1 (2025-09-09)：</strong>修正美日加澳過時與錯誤數據；加入顯著效益、兒科延長說明。</li>
        <li><strong>v1.0 (原始版本)：</strong>存在多項過時敘述（美國稅收 50%、日本單一 5 萬人、澳洲 2,000 人等）。</li>
      </ul>
    </section>

    <!-- Disclaimer -->
    <section id="disclaimer" class="disclaimer">
      <strong>免責聲明：</strong>本文件供政策研究與教育參考，非法律意見。實務適用請以各主管機關最新正式公告、法規原文與審議指引為準。對基於本文所為決策所生風險，請另行取得專業法規與藥事諮詢。
    </section>

  </div>

  <button class="back-to-top" title="回到頂部" onclick="window.scrollTo({top:0,behavior:'smooth'})">↑</button>

  <script>
    const backBtn = document.querySelector('.back-to-top');
    window.addEventListener('scroll',() => {
      if(window.scrollY > 320){
        backBtn.style.display='block';
      } else {
        backBtn.style.display='none';
      }
    });
    document.querySelectorAll('a[href^="#"]').forEach(a=>{
      a.addEventListener('click',e=>{
        const id = a.getAttribute('href');
        if(id.length>1){
          e.preventDefault();
          const target=document.querySelector(id);
          if(target){ target.scrollIntoView({behavior:'smooth',block:'start'}); }
        }
      });
    });
  </script>
</body>
</html>
